Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-ethyl-N-isopropyl-3-methyl-5-{[(2S)-2-(pyridin-4-ylamino)propyl]oxy}benzamide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
N-Ethyl-N-isopropyl–3-methyl–5-{[(2S)-2-(pyridin‑4‑ylamino)propyl]oxy}benzamide is a synthetic small molecule belonging to the class of n,n-dialkyl-m-toluamides and benzamides. It has a molecular formula of C21H29N3O2 and a molecular weight of approximately 355.47 g/mol[1][4][7]. The compound is listed as an experimental pharmaceutical in chemical databases, but there are no approved indications, clinical trials, or detailed pharmacological mechanism data available in public sources[6]. Its structure suggests potential for pharmacological activity, but its precise mechanism of action, targets, and therapeutic applications have not been established or published in peer-reviewed literature[7].
- Other names
- N-Ethyl-N-Isopropyl-3-Methyl-5-{[(2s)-2-(Pyridin-4-Ylamino)propyl]oxy}benzamideN-Ethyl-N-isopropyl–3-methyl–5–{[(2S)-2-(pyridin–4–ylamino)propyl]oxy}benzamideN-Ethyl-N-isopropyl–3-methyl–5-[ (2S ) - 2 - ( pyridin – 4 – ylamino ) propoxy ] benzamide
Beyond the preview
Go deeper on N-ethyl-N-isopropyl-3-methyl-5-{[(2S)-2-(pyridin-4-ylamino)propyl]oxy}benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-ethyl-N-isopropyl-3-methyl-5-{[(2S)-2-(pyridin-4-ylamino)propyl]oxy}benzamide.